HX531

HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities[1][2][3].

Product Specifications

CAS Number

[188844-34-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; MDM-2/p53; RAR/RXR

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/hx531.html

Purity

99.87

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)C1=CC=C(C2=NC3=CC([N+]([O-])=O)=CC=C3N(C)C4=CC5=C(C(C)(C)CCC5(C)C)C=C42)C=C1

Molecular Formula

C29H29N3O4

Molecular Weight

483.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Konta T, et al. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem. 2001 Apr 20;276 (16) :12697-701. |[2]Yamauchi T, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest. 2001 Oct;108 (7) :1001-13.|[3]Atsuko Nakatsuka, et al. RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21 (Cip1) pathway in adipocytes. J Pathol. 2012 Apr;226 (5) :784-95.|[4]Wenrui Zhao, et al. RXR signaling targeted cancer therapy. January 2023The Innovation Life 1 (1) :100014